文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

PCV13序贯PPSV23在免疫抑制患者及HIV感染者中的3年免疫原性与加强应答

Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV-3-year Follow-up of a Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

这项前瞻性队列研究的3年随访评估了HIV感染者、免疫抑制治疗患者及免疫正常对照在接种PCV13后2个月序贯PPSV23的长期免疫原性。从第4个月到第36个月,血清保护率在HIV感染者中从44%降至9%,免疫抑制治疗患者从55%降至17%,对照从82%降至42%。对M36血清转阴的初始应答者接种PCV20后,快速回忆应答仅见于PCV血清型,PPSV23共享血清型无显著抗体升高。

要点

  • HIV感染者和免疫抑制治疗患者接种PCV13序贯PPSV23后3年血清保护率显著下降。
  • 仅少数HIV感染者和免疫抑制患者、不足半数对照在3年时仍保持血清保护。
  • PCV20加强后快速回忆应答仅限于PCV血清型,PPSV23共享血清型无应答。

核心结论

  • HIV感染者和免疫抑制治疗患者接种PCV13序贯PPSV23后3年仅少数保持血清保护,对照亦不足半数。
  • PCV20加强后的快速回忆应答仅见于PCV血清型,提示未来应关注高价PCV的扩展基础免疫方案。

研究设计与样本

  • 前瞻性队列研究的3年随访,纳入HIV感染者、接受免疫抑制治疗的患者及免疫正常对照。
  • 所有受试者接种PCV13后2个月序贯PPSV23,在PCV13后3年(M36)检测全部24种疫苗血清型IgG水平。
  • 对基础免疫后2个月(M4)有应答但M36血清转阴者,接种PCV20加强后7天评估快速回忆应答。

主要发现

  • M4至M36,血清保护率在HIV感染者中从44%(22/50)降至9%(5/55)。
  • M4至M36,血清保护率在免疫抑制治疗患者中从55%(59/108)降至17%(22/131)。
  • M4至M36,血清保护率在对照中从82%(14/17)降至42%(8/19)。
  • 快速回忆应答在HIV感染者中为40%(4/10),免疫抑制单药治疗者为14%(2/14),联合治疗者为22%(2/9),对照为67%(2/3)。
  • PCV20/PCV13共享血清型中7/13抗体水平显著升高,而PCV20/PPSV23共享血清型中0/7显著升高。

关键数值与推荐

  • 血清保护率定义为24种疫苗血清型中17种IgG浓度≥1.3 μg/mL。
  • 快速回忆应答在PCV20加强后7天评估。

临床怎么用

  • 对HIV感染者和免疫抑制治疗患者,PCV13序贯PPSV23后3年血清保护率低,需关注长期保护减弱。
  • PCV20加强可诱导对PCV血清型的快速回忆应答,但对PPSV23共享血清型无显著提升。
  • 未来在免疫抑制人群中可考虑使用高价PCV(如PCV20)扩展基础免疫方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unclear among immunocompromised patients (ICPs). METHODS: This 3-year follow-up of a previously reported prospective cohort study included people with human immunodeficiency virus (HIV) (PWH), patients on immunosuppressive therapy, and immunocompetent controls who received PCV13 followed by PPSV23 2 months later. IgG levels for all 24 vaccine serotypes were measured 3 years after PCV13 (M36). The primary outcome was the seroprotection rate (SPR) at M36, defined as IgG concentrations ≥1.3 μg/mL for 17/24 vaccine serotypes. To assess immunological memory, we measured rapid recall responses 7 days after a PCV20 booster vaccination among initial responders 2 months after the priming schedule (M4) who had sero-reverted at M36. RESULTS: Between M4 to M36, SPRs dropped from 44% (22/50) to 9% (5/55) in PWH, from 55% (59/108) to 17% (22/131) in patients on immunosuppressive therapy and from 82% (14/17) to 42% (8/19) in controls. Rapid recall responses were observed in 40% (4/10) of PWH, 14% (2/14) of patients on immunosuppressive monotherapy, 22% (2/9) of patients on combination therapy, and 67% (2/3) of controls. Antibody levels increased significantly for 7/13 PCV20/PCV13-shared serotypes, but for none (0/7) of the PCV20/PPSV23-shared serotypes. CONCLUSIONS: Only a minority of PWH and patients on immunosuppressive therapy and under half of controls remained seroprotected 3 years after vaccination. As rapid recall responses were limited to PCV serotypes, future research in ICPs should focus on expanded priming schedule with higher-valent PCVs such as PCV20.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schnyder JL, Haggenburg S, Garcia Garrido HM, et al. Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV-3-year Follow-up of a Prospective Cohort Study. Clin Infect Dis. 2025. PMID: 40794691. doi:10.1093/cid/ciaf438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。